Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice

Molecular Interventions
Robert KindersJames H Doroshow

Abstract

The Food and Drug Administration (FDA) recently introduced the Exploratory Investigational New Drug Guidance to expedite the clinical evaluation of new therapeutic and imaging agents. Early clinical studies performed under the auspices of this guidance, so-called "Phase 0" trials, have been initiated at the National Cancer Institute to integrate qualified pharmacodynamic biomarker assays into first-in-human cancer clinical trials of molecularly targeted agents. The goal of this integration is to perform molecular proof-of-concept investigations at the earliest stage of cancer drug development. Phase 0 trials do not offer any possibility of patient benefit; instead, intensive, real-time pharmacodynamic and pharmacokinetic analyses of patient tumor samples and/or surrogate tissues are performed to inform subsequent trials. Phase 0 studies do not replace formal Phase I drug safety testing and require a substantial investment of resources in assay development early on; however, they offer the promise of more rational selection of agents for further, large-scale development as well as the molecular identification of potential therapeutic failures early in the development process.

Citations

Jul 11, 2008·Cancer Chemotherapy and Pharmacology·Chris H Takimoto
Sep 25, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Angelica Fasolo, Cristiana Sessa
Jun 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anthony J MurgoJames H Doroshow
Feb 4, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Roberto Jun AraiArnold Stern
Jan 20, 2010·Breast Cancer Research : BCR·Robert Clarke
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shivaani KummarJames H Doroshow
May 18, 2011·Perspectives in Clinical Research·Umesh Chandra GuptaVaibhav Choudhary
Feb 21, 2014·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Grant SugiuraWalter Mier
Nov 1, 2009·Future Medicinal Chemistry·James H Doroshow, Shivaani Kummar
Oct 3, 2015·Leukemia & Lymphoma·Pernille SvendsenHans E Johnsen
Nov 17, 2015·Expert Review of Molecular Diagnostics·Adrien SaliouJean-Yves Pierga
Mar 1, 2010·Expert Opinion on Medical Diagnostics·Andrea Staratschek-Jox, Joachim L Schultze
Jan 19, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michel Adamina, Markus Joerger
May 10, 2011·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Jeffrey L Cummings
Oct 12, 2010·Advanced Drug Delivery Reviews·Célia M GomesErnest K J Pauwels
Dec 19, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Shivaani KummarUNKNOWN Task Force on Methodology for the Development of Innovative Cancer Therapies (MDICT)
Apr 27, 2010·Statistics in Medicine·Larry V RubinsteinJames H Doroshow
Feb 27, 2016·Clinical and Translational Science·T BurtM Rowland
Nov 8, 2011·Cancer Biology & Therapy·Séverine MollardFranck G Sturtz
Dec 26, 2008·Clinical Pharmacology and Therapeutics·J M Collins
Sep 25, 2016·Seminars in Oncology·Katherine V Ferry-GalowRalph E Parchment
Jun 25, 2016·Cancer Medicine·Palak R ParekhChristophe E Redon
Sep 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marc PocardDominique Bellet
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patricia M LoRusso
Jan 8, 2013·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Leili FatehiSamuel Wickline
Mar 19, 2019·Therapeutic Drug Monitoring·Gareth J VealEtienne Chatelut
Mar 10, 2010·Nature Biotechnology·Henry I Miller
Sep 15, 2012·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Ryuichi Kato
Sep 1, 2017·Nature Biomedical Engineering·Penelope M TsimbouriMatthew J Dalby
Jun 20, 2020·Genome Génome / Conseil National De Recherches Canada·Cassandra Millet-BoureimaChiara Gamberi
Apr 18, 2015·Expert Opinion on Pharmacotherapy·Eleni AndreopoulouHayley M McDaid
May 30, 2013·American Society of Clinical Oncology Educational Book·Herbert H Loong, Lillian L Siu
Dec 3, 2009·Cancer Prevention Research·Thomas W Kensler, John D Groopman
Jun 19, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emily AbdolerDavid Wendler
Dec 21, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoSteven D Averbuch
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Patricia M LoRussoLesley Seymour
Jun 22, 2011·Bulletin du cancer·Marie-Quitterie PicatSimone Mathoulin-Pélissier

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Anthony J MurgoJames H Doroshow
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Shivaani KummarJames H Doroshow
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Emily AbdolerDavid Wendler
Nature Reviews. Drug Discovery
Ismail Kola, John Landis
© 2021 Meta ULC. All rights reserved